Equities Analysts Offer Predictions for ZVRA Q1 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - William Blair increased their Q1 2025 EPS estimates for shares of Zevra Therapeutics in a report issued on Wednesday, March 12th. William Blair analyst S. Corwin now anticipates that the company will earn ($0.24) per share for the quarter, up from their previous forecast of ($0.30). The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. William Blair also issued estimates for Zevra Therapeutics' Q2 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.65) EPS and FY2026 earnings at $0.12 EPS.

A number of other equities analysts have also recently weighed in on the stock. Canaccord Genuity Group upped their price objective on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a research report on Thursday, March 13th. JMP Securities set a $18.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Guggenheim increased their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, March 13th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Finally, Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $22.29.

Remove Ads

Zevra Therapeutics Price Performance

NASDAQ:ZVRA traded down $0.38 during trading hours on Friday, reaching $7.97. 319,016 shares of the company were exchanged, compared to its average volume of 574,467. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The stock's 50-day moving average is $7.92 and its 200-day moving average is $8.17. The firm has a market cap of $431.30 million, a PE ratio of -4.05 and a beta of 1.98. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.28). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The firm had revenue of $12.00 million during the quarter, compared to analyst estimates of $8.93 million.

Institutional Trading of Zevra Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Woodline Partners LP raised its holdings in Zevra Therapeutics by 2.2% during the fourth quarter. Woodline Partners LP now owns 4,139,593 shares of the company's stock worth $34,524,000 after purchasing an additional 90,940 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its position in shares of Zevra Therapeutics by 462.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company's stock worth $30,441,000 after acquiring an additional 3,001,000 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Zevra Therapeutics by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 2,824,212 shares of the company's stock worth $23,554,000 after acquiring an additional 68,151 shares during the last quarter. FMR LLC grew its position in shares of Zevra Therapeutics by 282,687.5% during the third quarter. FMR LLC now owns 2,313,202 shares of the company's stock worth $16,054,000 after acquiring an additional 2,312,384 shares during the last quarter. Finally, Altium Capital Management LLC grew its position in shares of Zevra Therapeutics by 8.8% during the fourth quarter. Altium Capital Management LLC now owns 1,850,000 shares of the company's stock worth $15,429,000 after acquiring an additional 150,000 shares during the last quarter. Institutional investors and hedge funds own 35.03% of the company's stock.

Insider Activity

In related news, EVP Joshua Schafer sold 10,500 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $82,530.00. Following the sale, the executive vice president now owns 29,486 shares of the company's stock, valued at $231,759.96. This trade represents a 26.26 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO R. Laduane Clifton sold 11,000 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the completion of the sale, the chief financial officer now directly owns 51,361 shares in the company, valued at approximately $403,697.46. This trade represents a 17.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 85,773 shares of company stock valued at $674,176. 2.40% of the stock is currently owned by company insiders.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.